Literature DB >> 17415081

Cognitive heterogeneity in schizophrenia.

Eileen M Joyce1, Jonathan P Roiser.   

Abstract

PURPOSE: Further clarification of the nature of cognitive heterogeneity in schizophrenia is needed to aid the endophenotype approach to the understanding of the genetic basis of the disorder. This review summarizes recent neuropsychological studies of schizophrenia, aimed at establishing whether there are valid forms of cognitive impairment that can be defined with the use of neuropsychological measures in patients with schizophrenia, and studies that have attempted to relate specific neuropsychological findings to genetic polymorphisms. RECENT
FINDINGS: There is good evidence for significant cognitive heterogeneity in schizophrenia. It is not yet clear, however, whether this heterogeneity is better accounted for by a general loss of function, varying in degree between different patients, or by impairment in specific cognitive abilities, for example working memory. Molecular genetic studies have provided evidence for associations of single nucleotide polymorphisms with both specific and general impairments, with some additional support for a working memory deficit from neuroimaging studies.
SUMMARY: Larger, better controlled studies are needed before the genetic sources of cognitive heterogeneity in schizophrenia can be accurately characterized. This will be aided with the development and use of more specific neuropsychological tasks that can accurately discriminate between different cognitive domains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415081      PMCID: PMC2597188          DOI: 10.1097/YCO.0b013e3280ba4975

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  49 in total

1.  Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes.

Authors:  R E Straub; C J MacLean; Y Ma; B T Webb; M V Myakishev; C Harris-Kerr; B Wormley; H Sadek; B Kadambi; F A O'Neill; D Walsh; K S Kendler
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

2.  Influences on cognitive heterogeneity in schizophrenia.

Authors:  G Goldstein; W J Shemansky
Journal:  Schizophr Res       Date:  1995-12       Impact factor: 4.939

3.  Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow.

Authors:  B-C Ho; T H Wassink; D S O'Leary; V C Sheffield; N C Andreasen
Journal:  Mol Psychiatry       Date:  2005-03       Impact factor: 15.992

4.  The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia.

Authors:  Takashi Ohnishi; Ryota Hashimoto; Takeyuki Mori; Kiyotaka Nemoto; Yoshiya Moriguchi; Hidehiro Iida; Hiroko Noguchi; Tetsuo Nakabayashi; Hiroaki Hori; Mayu Ohmori; Ryoutaro Tsukue; Kimitaka Anami; Naotugu Hirabayashi; Seiichi Harada; Kunimasa Arima; Osamu Saitoh; Hiroshi Kunugi
Journal:  Brain       Date:  2005-12-05       Impact factor: 13.501

5.  No, it is not possible to be schizophrenic yet neuropsychologically normal.

Authors:  Christopher M Wilk; James M Gold; Robert P McMahon; Katherine Humber; Virginia N Iannone; Robert W Buchanan
Journal:  Neuropsychology       Date:  2005-11       Impact factor: 3.295

Review 6.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

7.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.

Authors:  M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

8.  Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine.

Authors:  Venkata S Mattay; Terry E Goldberg; Francesco Fera; Ahmad R Hariri; Alessandro Tessitore; Michael F Egan; Bhaskar Kolachana; Joseph H Callicott; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

9.  Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives.

Authors:  Vera Golimbet; Inga Gritsenko; Margarita Alfimova; Irina Lebedeva; Tatyana Lezheiko; Lilia Abramova; Vasily Kaleda; Richard Ebstein
Journal:  World J Biol Psychiatry       Date:  2006       Impact factor: 4.132

10.  Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene.

Authors:  Janusz K Rybakowski; Alina Borkowska; Maria Skibinska; Aleksandra Szczepankiewicz; Pawel Kapelski; Anna Leszczynska-Rodziewicz; Piotr M Czerski; Joanna Hauser
Journal:  Psychiatry Clin Neurosci       Date:  2006-02       Impact factor: 5.188

View more
  38 in total

Review 1.  Targeting the hippocampal mossy fiber synapse for the treatment of psychiatric disorders.

Authors:  Katsunori Kobayashi
Journal:  Mol Neurobiol       Date:  2009-01-08       Impact factor: 5.590

2.  Inclusion of cognitive impairment in the DSM diagnosis of schizophrenia: if not now, when?

Authors:  Siow-Ann Chong
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

3.  Brain activation patterns during visual episodic memory processing among first-degree relatives of schizophrenia subjects.

Authors:  Erin Stolz; Krishna M Pancholi; Dhruman D Goradia; Sarah Paul; Matcheri S Keshavan; Vishwajit L Nimgaonkar; Konasale M Prasad
Journal:  Neuroimage       Date:  2012-08-21       Impact factor: 6.556

4.  Cognition and community functioning in schizophrenia: The nature of the relationship.

Authors:  Susan S Kuo; Laura Almasy; Ruben C Gur; Konasale Prasad; David R Roalf; Raquel E Gur; Vishwajit L Nimgaonkar; Michael F Pogue-Geile
Journal:  J Abnorm Psychol       Date:  2018-02

Review 5.  Dopamine: Functions, Signaling, and Association with Neurological Diseases.

Authors:  Marianne O Klein; Daniella S Battagello; Ariel R Cardoso; David N Hauser; Jackson C Bittencourt; Ricardo G Correa
Journal:  Cell Mol Neurobiol       Date:  2018-11-16       Impact factor: 5.046

Review 6.  Cognitive control deficits in schizophrenia: mechanisms and meaning.

Authors:  Tyler A Lesh; Tara A Niendam; Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

Review 7.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

8.  Clustering by neurocognition for fine mapping of the schizophrenia susceptibility loci on chromosome 6p.

Authors:  S-H Lin; C-M Liu; Y-L Liu; C Shen-Jang Fann; P-C Hsiao; J-Y Wu; S-I Hung; C-H Chen; H-M Wu; Y-S Jou; S K Liu; T J Hwang; M H Hsieh; C-C Chang; W-C Yang; J-J Lin; F H-C Chou; S V Faraone; M T Tsuang; H-G Hwu; W J Chen
Journal:  Genes Brain Behav       Date:  2009-07-21       Impact factor: 3.449

9.  State-space analysis of working memory in schizophrenia: an fBIRN study.

Authors:  Firdaus Janoos; Gregory Brown; Istvan A Mórocz; William M Wells
Journal:  Psychometrika       Date:  2012-12-29       Impact factor: 2.500

10.  Identification of SHANK2 Pathogenic Variants in a Chinese Uygur Population with Schizophrenia.

Authors:  Han Zhang; Dong Wang; Jianhua Chen; Xiuli Li; Qizhong Yi; Yongyong Shi
Journal:  J Mol Neurosci       Date:  2020-09-08       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.